Composition & Specifications
What is Empagliflozin 10 Mg and Linagliptin 5 Mg Tablet?
\n
Gisemepa 10/5 mg is a brand name of Empagliflozin 10 mg Linagliptin 5 mg are two antidiabetic medicines. Empagliflozin works by removing excess glucose from your body through urine and linagliptin works by lowering glucose production in the liver delaying glucose absorption from intestines and increases the body’s sensitivity to insulin. It is completely safe to buy from www.saturnformulations.in at the most affordable price in India.
\n
Uses of Empagliflozin linagliptin Tablet
\n
\n - Enhanced Glycemic control: The combination of Empagliflozin and linagliptin targets different pathways to lower blood glucose levels. While empagliflozin promotes the excretion of glucose through urine whereas linagliptin improves insulin secretion and reduces hepatic glucose production. This dual action helps in achieving more consistent and effective control of blood sugar.
\n
\n
\n - Cardiovascular benefits: Empagliflozin has shown a significant cardiovascular benefit in patients with diabetes and established cardiovascular disease. It lowers blood glucose and reduces cardiovascular risks hence this combination provides holistic care for individuals at risk of heart complications.
\n
\n
\n - Weight Loss and Fat Reduction: Empagliflozin mechanism of glucose excretion through urine results in a modest reduction of the body weight. This is beneficial for patients with type 2 diabetes who are also managing obesity, a common comorbidity in this population. Linagliptin on the other hand does not lead to weight gain and makes the combination therapy weight-neutral.
\n
\n
Precautions and Side effects of Empagliflozin 10 Mg and Linagliptin 5 Mg Tablet
\n
\n - Pregnancy: It might cause harm to an unborn baby and inform your healthcare provider if you are pregnant or planning to outweigh the risk and set the appropriate dosage.
\n - Breastfeeding: Empagliflozin Linagliptin tablet 10/5 mg might pass into breast milk so consult your healthcare provider as they will advise if you should stop breastfeeding.
\n - Liver or Kidney Disease: If you are suffering from Kidney or liver disease or have history so do not take this medicine without prescription from a doctor.
\n - Alcohol: Do not consume alcohol with Empagliflozin 10 MG and Linagliptin 5 mg tablets as it might have adverse effects on healthcare.
\n
\n
Side Effects:
\n
\n - Urinary Tract Infections (UTIs)
\n - Genital Fungal Infections
\n - Dehydration
\n - Hypotension
\n
\n
As you have complete information about Empagliflozin 10 Mg and Linagliptin 5 Mg Tablet and want to buy so visit www.saturnformulations.in at the genuine price in India.
📋 Certificate of AnalysisBatch-specific CoA from NABL-accredited lab available for every product.
🏅 GMP Schedule MManufactured under Drugs & Cosmetics Act GMP Schedule M standards.
🔬 Third-Party TestedEvery batch independently tested by NABL-accredited laboratory before dispatch.
📞 Request Product Dossier — For full composition details, pack sizes, and franchise pricing, contact us on
+91-8729000609 or
WhatsApp us.
Prescribing & Administration Information
⚠️ For Healthcare Professionals & Franchise Partners Only: This product is sold through licensed PCD franchise partners and authorised stockists. Prescribing, dosage, and administration information is available in the product literature and Patient Information Leaflet (PIL) supplied with each batch.
Dosage & Administration
As directed by the prescribing physician. Dosage varies by indication, patient age, and clinical condition. Full prescribing information included with product.
Storage Conditions
Store in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children. Do not use after expiry date printed on the pack.
Available Documentation
📄Product Information Leaflet (PIL) — included with every batch
🔬NABL-accredited Certificate of Analysis (CoA) — available on request per batch
📋Drug License compliance documents — provided with franchise agreement
🏅WHO-GMP manufacturing certificate — available for regulatory submission
